Fig. 5: CLDN18.2 and mesothelin AND-Gate is safe and promotes long-term efficacy.
From: On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models
A Experimental schematic (created in BioRender. Birocchi, F. (2025) https://BioRender.com/foaa417). GSU-bearing B2mKO NSG mice (2 × 10⁶ GSU tumor cells, subcutaneously) were treated intravenously with 3 × 10⁶ CAR-T cells (as indicated)(n = 5 mice per group). B Tumor volume (mean ± s.d.). C Body weight change compared to pre-treatment (mean ± s.d.). D Survival plot. E Absolute count of CAR-T cells in the peripheral blood at 7, 14, and 21 days post CAR-T cell injection. F Experimental schematic (created in BioRender. Birocchi, F. (2025) https://BioRender.com/foaa417): NSG mice bearing subcutaneous GSU tumors (2 × 10⁶ cells) were treated intravenously with CAR-T cells as indicated. Eight days post-treatment, mice were euthanized, and tumors and stomach tissues were harvested for immunohistochemistry analysis (n = 5 mice per group). G, H Quantification of human CD3⁺ cells per mm² of tissue in the stomach (G) and tumor (H) of treated mice, performed using QuPath software (Kruskal-Wallis test).
